As of October 2020 management of Coronavirus disease 2019 (COVID-19) is based on supportive care and off-label or compassionate-use therapies. On March 2020 tocilizumab - an anti-IL-6 receptor monoclonal antibody - was suggested as immunomodulatory treatment in severe COVID-19 because hyperinflammatory syndrome occurs in many patients similarly to the cytokine release syndrome that develops after CAR-T cell therapy. In our retrospective observational study, 20 severe COVID-19 patients were treated with tocilizumab in addition to standard-of-care therapy (SOC) and compared with 13 COVID-19 patients receiving only SOC. Clinical respiratory status, inflammatory markers and vascular radiologic score improved after one week from tocilizumab administration. On the contrary these parameters were stable or worsened in patients receiving only SOC. Despite major study limitations, improvement of alveolar-arterial oxygen gradient as well as vascular radiologic score after one week may account for improved pulmonary vascular perfusion and could explain the more rapid recovery of COVID-19 patients receiving tocilizumab compared to controls.

Pulmonary vascular improvement in severe COVID-19 patients treated with tocilizumab / Salvati, Lorenzo; Occhipinti, Mariaelena; Gori, Leonardo; Ciani, Luca; Mazzoni, Alessio; Maggi, Laura; Capone, Manuela; Parronchi, Paola; Liotta, Francesco; Miele, Vittorio; Annunziato, Francesco; Lavorini, Federico; Cosmi, Lorenzo. - In: IMMUNOLOGY LETTERS. - ISSN 0165-2478. - STAMPA. - (2020), pp. 0-0. [10.1016/j.imlet.2020.10.009]

Pulmonary vascular improvement in severe COVID-19 patients treated with tocilizumab

Salvati, Lorenzo;Occhipinti, Mariaelena;Ciani, Luca;Mazzoni, Alessio;Maggi, Laura;Capone, Manuela;Parronchi, Paola;Liotta, Francesco;Miele, Vittorio;Annunziato, Francesco;Lavorini, Federico;Cosmi, Lorenzo
2020

Abstract

As of October 2020 management of Coronavirus disease 2019 (COVID-19) is based on supportive care and off-label or compassionate-use therapies. On March 2020 tocilizumab - an anti-IL-6 receptor monoclonal antibody - was suggested as immunomodulatory treatment in severe COVID-19 because hyperinflammatory syndrome occurs in many patients similarly to the cytokine release syndrome that develops after CAR-T cell therapy. In our retrospective observational study, 20 severe COVID-19 patients were treated with tocilizumab in addition to standard-of-care therapy (SOC) and compared with 13 COVID-19 patients receiving only SOC. Clinical respiratory status, inflammatory markers and vascular radiologic score improved after one week from tocilizumab administration. On the contrary these parameters were stable or worsened in patients receiving only SOC. Despite major study limitations, improvement of alveolar-arterial oxygen gradient as well as vascular radiologic score after one week may account for improved pulmonary vascular perfusion and could explain the more rapid recovery of COVID-19 patients receiving tocilizumab compared to controls.
2020
0
0
Goal 3: Good health and well-being for people
Salvati, Lorenzo; Occhipinti, Mariaelena; Gori, Leonardo; Ciani, Luca; Mazzoni, Alessio; Maggi, Laura; Capone, Manuela; Parronchi, Paola; Liotta, Francesco; Miele, Vittorio; Annunziato, Francesco; Lavorini, Federico; Cosmi, Lorenzo
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1216194
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 11
  • ???jsp.display-item.citation.isi??? 10
social impact